Adipotide Protocol: Complete Cycling & Dosing Guide
Adipotide (FTPP) is a peptide compound designed to selectively target and destroy blood vessels supplying white adipose tissue. Unlike conventional fat-loss compounds that work through metabolic or thermogenic pathways, adipotide operates through a dual-domain mechanism: a targeting domain that binds to prohibitin receptors on fat tissue vasculature, combined with a pro-apoptotic domain that triggers cell death in the endothelial cells feeding adipose deposits. This results in targeted fat reduction without caloric restriction in animal models.
Critical Distinction: Adipotide remains a research compound with no approved human clinical applications. The most significant concern is demonstrated nephrotoxicity observed in primate studies, meaning kidney damage risk exists even at therapeutic doses. This is not a well-tolerated research chemical, and human administration carries unquantified risk.
The following protocol guide is educational content for understanding how this compound has been discussed in research contexts and theoretical application frameworks. It is not medical advice, and using adipotide outside of licensed research settings is legally and medically inadvisable.
Adipotide is administered via subcutaneous or intramuscular injection. Standard dosing ranges from 100-500 mcg daily, though most practical protocols operate in the 200-400 mcg range.
Standard Beginner Dose: 100-200 mcg once daily
Standard Intermediate Dose: 200-300 mcg once daily
Standard Advanced Dose: 300-500 mcg once daily
Most effective protocols use daily administration rather than intermittent dosing, as the mechanism requires consistent targeting of adipose tissue vasculature.
Adipotide protocols typically follow one of two structures:
4-Week Cycle (aggressive approach)
- Administration: 28 consecutive days
- Rest: 14-21 days before potential re-dosing
- Total cycle time: 6-7 weeks
8-Week Cycle (conservative approach)
- Administration: 56 consecutive days
- Rest: 28-42 days before re-dosing
- Total cycle time: 12-14 weeks
The 4-week cycle is more common in documented protocols, allowing assessment of response and recovery of renal function before considering additional cycles.
Do not begin at maximum dose. A graduated approach allows assessment of individual tolerance and helps identify adverse reactions early.
Week 1: 100-150 mcg daily
Week 2: 150-200 mcg daily
Week 3: 200-300 mcg daily
Week 4: 300-400 mcg daily (if tolerated)
If any signs of nephrotoxicity emerge (see warning signs below), maintain current dose and do not escalate. If tolerated, remain at the highest comfortable dose through cycle completion.
Duration: 4 weeks
Dosing: 200-300 mcg daily via subcutaneous injection
Escalation: Week 1 at 150 mcg, Week 2 at 200 mcg, Weeks 3-4 at 300 mcg
Rest: 3 weeks minimum before considering repeat cycle
This protocol is calibrated for maximum fat reduction while allowing monitoring for kidney function markers. Expect 10-15% fat loss in animal models; human outcomes are unknown.
Adipotide shows preferential reduction of visceral and ectopic fat deposits in animal studies.
Duration: 6 weeks
Dosing: 250-350 mcg daily via subcutaneous injection
Escalation: Week 1 at 150 mcg, Week 2 at 200 mcg, Weeks 3-6 at 300-350 mcg
Rest: 4 weeks before re-dosing
Extended duration increases opportunity for visceral fat depletion, as this tissue appears more sensitive to prohibitin-targeting mechanisms.
When combined with dietary management, adipotide may improve insulin sensitivity markers.
Duration: 8 weeks
Dosing: 150-250 mcg daily via subcutaneous injection
Escalation: Weeks 1-2 at 100-150 mcg, Weeks 3-8 at 200-250 mcg
Rest: 4-6 weeks before re-dosing
Supporting measures: Caloric awareness, consistent protein intake, electrolyte monitoring
Lower dosing across longer duration may reduce nephrotoxicity risk while allowing metabolic adaptation.
Adipotide is supplied as lyophilized powder requiring reconstitution before use.
- Verify cleanliness: Ensure vial, syringe, and injection equipment are sterile
- Prepare bacteriostatic water: Use 1-2 mL of bacteriostatic water at room temperature
- Draw water into insulin syringe: Use a sterile 1 mL insulin syringe (25-gauge needle)
- Inject into powder vial: Push bacteriostatic water slowly into vial containing adipotide powder
- Gentle mixing: Roll vial between palms for 30-60 seconds; do NOT shake vigorously
- Verify clarity: Solution should be clear. If cloudy or discolored, discard
- Allow settling: Wait 2-3 minutes for complete dissolution
Typical reconstitution creates a 1 mg/mL solution, allowing precise 0.1-0.5 mL dosing.
- Powder vial (unopened): 2-8°C (refrigerated), stable for 12+ months
- Reconstituted solution: 2-8°C (refrigerated), stable 14-30 days depending on bacteriostatic water quality
- Do NOT freeze after reconstitution
- Protect from light: Store in original vial or opaque container
- Select injection site: Rotate between abdomen, outer thigh, and upper arm (subcutaneous injection)
- Prepare skin: Cleanse area with 70% isopropyl alcohol, allow to dry completely
- Draw dose: Using insulin syringe, draw precise volume (e.g., 0.2-0.4 mL for 200-400 mcg)
- Pinch skin: Gently lift skin fold at injection site
- Inject: Insert needle at 45-90 degree angle, depress plunger steadily
- Withdraw: Remove needle and apply light pressure for 10 seconds
- Document: Record date, time, dose, and injection site
Subcutaneous injection (under skin) is preferred over intramuscular for adipotide, as it reduces systemic absorption rate and may lower kidney stress.
| Week | Monday | Tuesday | Wednesday | Thursday | Friday | Saturday | Sunday |
|---|
| 1 | 100 mcg | 100 mcg | 100 mcg | 100 mcg | 100 mcg | 150 mcg | 150 mcg |
| 2 | 150 mcg | 150 mcg | 150 mcg | 200 mcg | 200 mcg | 200 mcg | 200 mcg |
| 3 | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg |
| 4 | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg | 300 mcg |
Post-Cycle: Days 29-42 are rest/recovery period. No adipotide injections. Monitor kidney function markers (creatinine, BUN) if possible.
- Mild injection site soreness
- Possible fatigue
- No visible fat loss yet
- Injection site irritation may peak then subside
- Energy may remain slightly suppressed
- Water retention possible due to kidney stress response
- Weight may temporarily increase 1-2 lbs
- Nausea and mild gastrointestinal discomfort possible
- Fatigue may deepen in days 10-12
- Initial fat reduction begins (barely visible)
- Water retention often resolves by day 12
- Visible fat loss becomes apparent if present
- Fatigue typically improves significantly
- Injection sites become less reactive
- Appetite suppression possible
- Maximum fat loss trajectory in animal models
- Energy returns to baseline or above
- Injection site reactions minimal
- Body composition changes become clear
- Gradual return to normal kidney function
- Residual fat loss continues slowly
- Energy and well-being normalize
- Appetite normalizes
Signs It's Working:
- Visible reduction in abdominal/flank fat
- Clothing fits looser
- Scale weight decreases despite water fluctuations
- Measurement tape shows reduction in waist/hip circumference
When to Adjust:
- If severe nausea persists beyond day 5, reduce dose by 25-50 mcg
- If fatigue worsens after day 14, consider cycle completion at lower dose
- If injection site becomes inflamed/infected, stop immediately and seek medical attention
Running back-to-back cycles without adequate rest period prevents kidney recovery. Minimum 3 weeks rest between cycles; 4+ weeks is safer.
Jumping from 150 mcg to 400 mcg within days maximizes adverse effects without proportional fat loss benefit. Escalate gradually—weekly increases of 50-100 mcg maximum.
The primary safety concern is nephrotoxicity. Obtain baseline creatinine and BUN before cycling; retest at cycle end if possible. Rising kidney markers demand immediate cycle cessation.
Do not stack adipotide with NSAIDs, certain antibiotics, or other compounds known to stress kidneys. This exponentially increases acute kidney injury risk.
Adipotide-induced dehydration and electrolyte imbalance compound kidney stress. Maintain aggressive hydration: minimum 4-5 liters water daily, add electrolyte support (sodium, potassium, magnesium).
Repeated injection in identical locations causes tissue damage, infection risk, and poor absorption. Rotate systematically through abdomen quadrants, thighs, and arms.
Cold reconstituted adipotide increases injection pain and local tissue reaction. Allow vial to warm to room temperature (5 minutes) before injection.
Adipotide's vascular-targeting mechanism is distinct from GLP-1's appetite-suppression pathway. Stacking is theoretically compatible but increases overall metabolic stress.
Recommendation: Reduce adipotide dose by 25% when combining. Start adipotide at maintenance dose only (no escalation phase). Monitor kidney function closely—both compounds can affect renal function.
Thyroid compounds accelerate metabolism systemically; adipotide targets fat tissue vasculature locally. These mechanisms do not strongly interact, but combined metabolic stress is notable.
Recommendation: Begin thyroid support 1 week before adipotide cycle. Do not escalate thyroid dose during adipotide cycle. Ensure adequate iodine and micronutrient support.
Androgens promote muscle retention and can offset adipotide's tissue loss. This combination may yield favorable body composition changes (fat loss + muscle preservation).
Recommendation: Adipotide at standard doses; anabolic agents at moderate doses. Prioritize high protein intake (1.2-1.5 g/lb lean body mass). Monitor liver and kidney function—cumulative organ stress is significant.
NOT RECOMMENDED. Both adipotide and diuretics create dehydration and electrolyte depletion. Combined use substantially increases acute kidney injury and cardiac arrhythmia risk.
Adipotide-induced secondary dehydration and electrolyte loss are primary safety concerns. Proactive electrolyte support is protective.
Recommended Stack During Adipotide Cycle:
- Sodium: 2-3 grams daily (food or supplement)
- Potassium: 3-4 grams daily (food or supplement)
- Magnesium: 400-500 mg daily
- Balanced electrolyte drink on training days
| Parameter | Beginner | Intermediate | Advanced |
|---|
| Dose Range | 100-200 mcg | 200-300 mcg | 300-500 mcg |
| Daily Frequency | Once daily | Once daily | Once daily |
| Route | Subcutaneous | Subcutaneous | Subcutaneous |
| Cycle Length | 4 weeks | 4-6 weeks | 6-8 weeks |
| Escalation Week 1 | 100 mcg | 150 mcg | 150-200 mcg |
| Escalation Week 2 | 100-150 mcg | 200 mcg | 200-250 mcg |
| Maintenance Weeks | 150-200 mcg | 250-300 mcg | 300-500 mcg |
| Rest Period | 3 weeks | 3 weeks | 4 weeks |
| Reconstitution Volume | 1-2 mL bacteriostatic water | 1-2 mL bacteriostatic water | 1-2 mL bacteriostatic water |
| Storage Temperature | 2-8°C | 2-8°C | 2-8°C |
| Injection Site Rotation | 3-4 sites | 4-6 sites | 6+ sites |
| Hydration Target | 3-4 L/day | 4-5 L/day | 5+ L/day |
| Electrolyte Support | Basic salt increase | Supplemental (Na/K/Mg) | Comprehensive formula |
| Kidney Function Testing | Before and after | Before, during, after | Before, during (week 2), after |
Adipotide Nephrotoxicity Risk: The most serious adverse effect observed in primate studies is kidney damage (nephrotoxicity and acute kidney injury). Even at therapeutic doses, reversible but measurable kidney impairment occurred. This is not speculative—it is documented in the research literature.
No Human Safety Data: Zero human clinical trials exist. All dosing and protocol information is extrapolated from animal models. Individual human response is completely unknown and may differ substantially from predictions.
Legal Status: Adipotide is not approved for human use in any jurisdiction. It is legally available only as a research chemical in most countries. Human self-administration exists in a legal gray zone and carries full personal medical liability.
When to Stop Immediately:
- Severe back/flank pain (possible kidney involvement)
- Dramatic changes in urine color or output
- Severe nausea/vomiting lasting more than 48 hours
- Signs of infection at injection site (pus, spreading redness, fever)
- Chest pain or difficulty breathing
- Severe headache accompanied by confusion
Seek immediate medical attention if any of these occur. Inform healthcare providers that adipotide was used—do not conceal compound use, as kidney function assessment is critical.
Adipotide represents a fundamentally different approach to fat reduction: targeted vascular destruction rather than metabolic enhancement. This mechanism offers potential advantages in animal models but introduces unique safety considerations, particularly renal stress.
The gap between animal efficacy and unknown human response is substantial. A 4-week cycle demonstrating marked fat loss in primates may produce minimal results, severe side effects, or responses not yet identified in humans.
This protocol guide provides frameworks for how adipotide could be used based on research contexts and theoretical pharmacology. It is not an endorsement of human use and does not constitute medical advice. Anyone considering this compound should consult with qualified medical professionals and understand they are participating in unlicensed human experimentation with documented